Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Provectus’ shares to begin trading on NYSE MKT on  May 16, 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed reports net loss of $1.5M in first quarter 2014

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

New paper offers new insights into role carcinoma-associated fibroblasts play in tumor biology

New paper offers new insights into role carcinoma-associated fibroblasts play in tumor biology

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma on the rise among Mexican Americans

CT-guided IRE therapy offers safe, feasible primary local treatment for advanced pancreatic cancer

CT-guided IRE therapy offers safe, feasible primary local treatment for advanced pancreatic cancer

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

FDA accepts Merck's MK-3475 BLA for review

FDA accepts Merck's MK-3475 BLA for review

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Liver cancer screening in cirrhosis patients improves survival rates

Liver cancer screening in cirrhosis patients improves survival rates

New biomarker shows promise in improving screening for esophageal cancer

New biomarker shows promise in improving screening for esophageal cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.